比较补阳还五颗粒与脑心通胶囊治疗稳定型心绞痛的随机盲法多中心临床试验的原理与设计
本研究为随机、盲法、平行对照、多中心临床试验方案,计划纳入128例稳定型心绞痛患者,在标准化西药治疗基础上按2:1:1随机分为脑心通胶囊组、补阳还五颗粒组和安慰剂组。主要结局为稳定型心绞痛症状评分改善的有效率,次要结局包括心电图、西雅图心绞痛问卷评分和硝酸甘油消耗量。
要点
- 在标准化西药治疗基础上,比较脑心通胶囊与补阳还五颗粒治疗稳定型心绞痛的疗效和安全性。
- 计划纳入128例患者,按2:1:1随机分为脑心通胶囊组、补阳还五颗粒组和安慰剂组。
- 主要结局为稳定型心绞痛症状评分改善的有效率,次要结局包括心电图、西雅图心绞痛问卷评分和硝酸甘油消耗量。
核心结论
- 本研究将评估脑心通胶囊与补阳还五颗粒治疗稳定型心绞痛的疗效和安全性,结果将为使用中草药治疗稳定型心绞痛提供关键证据。
研究设计与样本
- 随机、盲法、平行对照、多中心临床试验方案,计划纳入128例稳定型心绞痛患者。
- 在标准化西药治疗基础上,按2:1:1随机分为干预组1(脑心通胶囊组)、干预组2(补阳还五颗粒组)和对照组(安慰剂组)。
- 随机化前需进行2周导入期,研究包括1周基线期和4周治疗期。
关键数值与推荐
- 主要结局为稳定型心绞痛症状评分改善的有效率。
- 次要结局包括对心电图的影响、西雅图心绞痛问卷评分和硝酸甘油消耗量。
- 试验注册号为Chinese Clinical Trials Registry ChiCTR1800015191,注册日期为2018年3月13日。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Stable angina pectoris (SAP) currently seriously threatens the health of humans, and mortality is continuously rising. Current treatment strategies mainly include pharmaceutical therapy and revascularization. In China, Buyang Huanwu granules (BYHW) and Naoxintong capsules (NXT) have been used in the treatment of SAP, but it is not clear which agent is better in terms of relieving symptoms and improving quality of life. Therefore, we designed a clinical trial to compare the efficacy and safety of NXT and BYHW in the treatment of SAP. METHODS: This is a randomized, blinded, parallel controlled, multicentre clinical trial protocol. On the basis of standardized Western medicine treatment, a total of 128 SAP patients will be randomly divided into intervention group 1 (NXT group), intervention group 2 (BYHW group), and a control group (placebo group) at a 2:1:1 ratio. A 2-week run-in period is required prior to randomization, and a 1-week baseline period and 4-week treatment period are included in this study. The primary outcome is the efficacy rate of stable angina symptom score improvement; the secondary outcomes include the effect on electrocardiograms, Seattle Angina Questionnaire scores, and nitroglycerine consumption. DISCUSSION: This study will evaluate the efficacy and safety of NXT and BYHW in the treatment of SAP. The results will provide critical evidence for using Chinese herbal medicines to treat SAP. TRIAL REGISTRATION: Chinese Clinical Trials Registry ChiCTR1800015191. Registered on 13 March 2018. http://www.chictr.org.cn/showproj.aspx?proj=25818 . All the registration items can be found within the protocol.
引用
- Wang Y, Xu Y, Zhang L, et al. Comparison of Buyang Huanwu granules and Naoxintong capsules in the treatment of stable angina pectoris: rationale and design of a randomized, blinded, multicentre clinical trial. Trials. 2022. PMID: 35062988. doi:10.1186/s13063-021-05914-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。